Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 An
Go back to Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 An| Mirenco, Inc. (NASDAQ: MREO) | Delayed: 2.64 -0.01 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.65 | 52 Week High | $0.01 | |||
| Open | $2.62 | 52 Week Low | $0.00 | |||
| Day High | $2.67 | P/E | N/A | |||
| Day Low | $2.53 | EPS | $-0.02 | |||
| Volume | 912,723 | |||||
| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 42.37 -1.01 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.38 | 52 Week High | $117.12 | |||
| Open | $43.26 | 52 Week Low | $46.52 | |||
| Day High | $43.92 | P/E | N/A | |||
| Day Low | $41.07 | EPS | $-1.97 | |||
| Volume | 676,047 | |||||
